(Q42619331)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19406851%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

title

Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19406851%20AND%20SRC:MED&resulttype=core&format=json

major depressive disorder

27 January 2020

main subject

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19406851%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Antonella Valli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19406851%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

L S Volonteri

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19406851%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

G Cerveri

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19406851%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

A Fiorentini

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19406851%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

I F De Gaspari

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19406851%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

M C Mauri

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19406851%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

P Papa

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19406851%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

C Mencacci

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19406851%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

language of work or name

English

0 references

publication date

30 April 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19406851%20AND%20SRC:MED&resulttype=core&format=json

Journal of Psychopharmacology

27 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19406851%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19406851%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

1193-1199

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19406851%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19406851%20AND%20SRC:MED&resulttype=core&format=json

An Inventory for Measuring Depression

27 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

The tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Tolerability and efficacy of duloxetine in a nontrial situation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Duloxetine in treatment of anxiety symptoms associated with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Effects of duloxetine on painful physical symptoms associated with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

The assessment of anxiety states by rating

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Time course of depression-symptom improvement during treatment with duloxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Synthesis and biological activity of some known and putative duloxetine metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Long-term efficacy and therapeutic drug monitoring of sertraline in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Clinical outcome and tolerability of sertraline in major depression: a study with plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Rating depressed patients: observer- vs self-assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

A dose-finding study of duloxetine based on serotonin transporter occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863

An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109104863